SUPN logo

SUPN
Supernus Pharmaceuticals Inc

2,372
Mkt Cap
$2.76B
Volume
622,225.00
52W High
$59.68
52W Low
$29.16
PE Ratio
-69.97
SUPN Fundamentals
Price
$47.85
Prev Close
$48.00
Open
$48.02
50D MA
$51.09
Beta
0.56
Avg. Volume
538,082.45
EPS (Annual)
-$0.6829
P/B
2.59
Rev/Employee
$924,102.83
$2,537.93
Loading...
Loading...
News
all
press releases
Supernus Pharmaceuticals, Inc. $SUPN Shares Sold by Pictet Asset Management Holding SA
Pictet Asset Management Holding SA cut its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 5.0% during the fourth quarter, according to the company in its most recent Form...
MarketBeat·3d ago
News Placeholder
More News
News Placeholder
Bausch Health (BHC) Lags Q1 Earnings Estimates
Bausch (BHC) delivered earnings and revenue surprises of -3.11% and +4.72%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4d ago
News Placeholder
Biogen Beats Q1 Earnings Estimates but Cuts 2026 EPS View on M&A Costs
Biogen beats Q1 earnings and revenue estimates, fueled by new drug growth, but cuts 2026 EPS outlook to reflect M&A costs.
Zacks·4d ago
News Placeholder
Supernus Pharmaceuticals (NASDAQ:SUPN) Rating Increased to Hold at Zacks Research
Zacks Research upgraded Supernus Pharmaceuticals from a "strong sell" rating to a "hold" rating in a report on Monday...
MarketBeat·4d ago
News Placeholder
Supernus Pharmaceuticals (SUPN) to Release Quarterly Earnings on Tuesday
Supernus Pharmaceuticals (NASDAQ:SUPN) will be releasing its Q1 2026 earnings after the market closes on Tuesday, May 5. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-5-supernus-pharmaceuticals-inc-stock...
MarketBeat·5d ago
News Placeholder
Biogen Q1 Earnings: Can New Launches Offset Declining MS Franchise?
Biogen heads into Q1 earnings with new drugs like Skyclarys and Zurzuvae driving growth as legacy MS products face rising competitive pressure.
Zacks·9d ago
News Placeholder
Ruffer LLP Sells 21,058 Shares of Supernus Pharmaceuticals, Inc. $SUPN
Ruffer LLP lessened its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 38.0% during the fourth quarter, according to its most recent filing with the Securities...
MarketBeat·11d ago
News Placeholder
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Receives Consensus Rating of "Hold" from Analysts
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Get Free Report) has been given an average recommendation of "Hold" by the seven analysts that are presently covering the firm, Marketbeat Ratings...
MarketBeat·13d ago
News Placeholder
Alpha Cognition Strengthens Its Board of Directors with Appointment of Bethany Sensenig
Alpha Cognition Inc. (Nasdaq: ACOG) (Alpha Cognition, or the Company), a biopharmaceutical company focused on developing novel therapies for debilitating neurodegenerative disorders, today announced the appointment of Bethany Sensenig to its Board of Directors, effective April 15, 2026. Ms...
Business Wire·13d ago
News Placeholder
Phocas Financial Corp. Acquires Shares of 81,320 Supernus Pharmaceuticals, Inc. $SUPN
Phocas Financial Corp. acquired a new stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 81,320 shares of the specialty pharmaceu...
MarketBeat·18d ago
<
1
2
...
>

Latest SUPN News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.